Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$183.11M$183.11Mderived−1.8% vs Q4 2024 Net Income$24.43M$24.43Mderived−35.7% vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$85,670,000−1.1% Operating Incomederived$35,606,000−21.1% Operating Cash Flowderived$32,863,000+13.2% Free Cash Flowderived$24,591,000+48.0% Margins · derivedGross margin46.8%+0.3 pt vs Q4 2024
Operating margin19.4%−4.8 pt vs Q4 2024
Net margin13.3%−7.0 pt vs Q4 2024
ended Dec 31, 2025 · filed Feb 26, 2026 · 57 d after period end